Precigen: August Is Pivotal For This Biotech Innovator

Every once in a while, I get things right. On January 31, 2023 , I rated Precigen (NASDAQ: PGEN ) a HOLD at 1.62.Sean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. ...